Acadia Pharmaceuticals shares fell 12.8% after its experimental Alzheimer's psychosis drug remlifanserin narrowly missed the primary endpoint in a Phase 2 study. The company still plans to advance the drug to Phase 3. Analysts see limited downside and maintain buy ratings, citing valuation floor and unmet need.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
